Last updated: February 13, 2026
Overview of NDC 00406-0803
NDC 00406-0803 corresponds to Ibrutinib (brand: Imbruvica), a targeted therapy used primarily for treating various hematologic malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. The drug is marketed and distributed by AbbVie and Janssen.
Market Landscape
-
Market Size and Growth
The global oncology therapeutics market was valued at approximately $150 billion in 2022, with targeted therapies comprising roughly 45%. Ibrutinib holds a commanding share within the hematologic malignancy segment, driven by approvals in multiple indications and its established efficacy.
The U.S. accounts for the largest share, with an estimated 50-60% of sales in this segment. Worldwide, the market for drugs targeting CLL and MCL is projected to grow at a Compound Annual Growth Rate (CAGR) of 8-10% through 2027, influenced by expanding indications and ongoing clinical trials [1].
-
Competitive Landscape
Ibrutinib faces competition from several drugs:
- Acalabrutinib (Calquence): Approved by FDA for CLL, offers an alternative with a different side-effect profile.
- Zanubrutinib (Brukinsa): Approved for MCL and CLL, with similar mechanism.
- Other emerging BTK inhibitors: Pirtobrutinib (LOXO-BREPKIN), in early phase trials for refractory cases.
-
Key Market Drivers and Barriers
Drivers:
- Proven efficacy and safety profile.
- Expanding indications in front-line and refractory settings.
- High patient adherence due to oral administration.
Barriers:
- Patent expirations and biosimilar entry planned for mid-2030s.
- Competition from generics and multiple BTK inhibitors.
- Cost containment pressures from payers.
Pricing History and Current Pricing
-
Historical Pricing Trends
- When launched in 2013, the average wholesale price (AWP) was approximately $18,000 per year.
- Over time, pricing adjustments have ranged from 3-7% annually, aligning with inflation and market dynamics.
- Current wholesale acquisition cost (WAC) for a 140 mg daily dose averages approximately $22,000–$25,000 annually.
-
Price Comparison with Competitors
| Drug |
Approved Indications |
Approximate Annual Cost |
Market Share (2022) |
| Ibrutinib |
CLL, MCL, Waldenström's |
$22,000–$25,000 |
70% (hematologic cancers) |
| Acalabrutinib |
CLL, MCL |
$22,000–$24,000 |
15% |
| Zanubrutinib |
CLL, MCL |
$20,000–$23,000 |
10% |
| Others |
Refractory or relapsed cases |
Varies |
5% |
Future Price Projections
-
Short-Term (Next 1-3 Years)
- No immediate major price reductions are expected, as patents protect Ibrutinib until approximately 2032–2035.
- Manufacturers may adjust prices slightly to reflect inflation, reimbursement pressures, or new indications.
-
Mid to Long-Term (3-10 Years)
- Patent expiration around 2032–2035 opens the market to biosimilars and generics.
- Price reductions of 50–70% are expected upon biosimilar entry, aligning with similar transitions in other biologics.
- The initial biosimilar versions could enter at 20-30% of current prices, gradually reducing the average market price.
-
Impact of Biosimilars
Data from recent biosimilar entries (e.g., infliximab, trastuzumab) show rapid price reductions post-launch. Market penetration is often limited initially but accelerates within 2-3 years.
-
Pricing under Payer and Policy Dynamics
- Payer pressure for value-based pricing and outcomes-based reimbursement is intensifying.
- Price negotiations with CMS and commercial payers may lead to discounts of 10–20% in voluntary agreements.
- Future reimbursement landscape will influence net prices more than list prices.
Summary
| Time Frame |
Outlook |
Expected Price Trend |
| 2023–2025 |
Stable pricing; slight adjustments |
Maintains current levels with minor variances |
| 2026–2031 |
Market retains exclusivity, new indications emerge |
Slight increases due to inflation, access expansion |
| Post-2032 |
Patent expiry, biosimilar entry |
Price declines of 50–70%, early versions near 30% of original |
Key Considerations for Stakeholders
- Investors should monitor patent protections and biosimilar approval pathways.
- Manufacturers will need to prepare for biosimilar market entry, adjusting pricing strategies accordingly.
- Payers will push for formulary tiers and discounts, influencing net prices.
- Clinicians will respond to evolving guidelines and safety profiles affecting utilization.
Key Takeaways
- Ibrutinib remains a dominant therapy; pricing has stabilized near $22,000–$25,000 annually.
- Patent expiration by the mid-2030s likely triggers significant price reductions.
- Competition from newer BTK inhibitors moderates price growth but currently maintains high market shares.
- Biosimilar entry will be the primary driver of future price declines.
- Payer pressures and policy reforms may influence net reimbursement levels before patent expiry.
FAQs
1. When does patent expiration for Ibrutinib occur?
Patent rights generally extend to 2032–2035, with possible extensions or legal challenges influencing exact timing.
2. How do biosimilars typically affect prices?
Biosimilar entries lead to price reductions of up to 70%, with discounts appearing within 1–3 years of approval.
3. Which indications are expected to grow the most?
New approvals for first-line treatments and combination therapies will expand market opportunities.
4. Are there emerging oral agents that could replace Ibrutinib?
Yes, agents like Pirtobrutinib and next-generation inhibitors are in trials but have not yet challenged Ibrutinib’s market share significantly.
5. How might healthcare policy impact future pricing?
Reimbursement reforms, value-based contracts, and increased drug price transparency could pressure net prices downward before patent expiry.
References
[1] Allied Market Research, "Global Oncology Therapeutics Market," 2022.
